Adma Biologics Stock Price, News & Analysis

ADMA Biologics reported strong second quarter 2022 results with total revenues of $33.9 million, a 90% year-over-year increase. Gross profit surged to $7.8 million, marking a 112% improvement from the previous quarter. The company narrowed net losses to $13.8 million, a 45% reduction from the first quarter. Full-year revenue guidance is set to exceed $130 million. Strategic expansions are ongoing, including plans for more FDA-licensed BioCenters. The company also anticipates achieving profitability by Q1 2024 with long-term revenue targets of up to $300 million.

ADMA Biologics, Inc. (Nasdaq: ADMA) will report its Q2 financial results for the period ended June 30, 2022, on August 10, 2022. The announcement includes a live conference call at 4:30 p.m. ET to discuss financial outcomes and company updates. ADMA specializes in manufacturing and marketing plasma-derived biologics, currently offering FDA-approved products for immunodeficient patients. The company operates a plasma fractionation facility in Boca Raton, Florida, and also runs FDA-approved plasma collection centers.

ADMA Biologics (Nasdaq: ADMA) announced its inclusion in the Russell 2000® Index, effective June 27, 2022, as per the preliminary list from FTSE Russell released on June 17, 2022. The Russell 2000® Index assesses the performance of small-cap stocks in the U.S. equity market and is a benchmark for numerous investment strategies, managing approximately $12 trillion in assets. ADMA specializes in plasma-derived biologics aimed at treating immunodeficient patients and has three FDA-approved products, including BIVIGAM® and ASCENIV™.

ADMA Biologics reported first quarter 2022 revenues of $29.1 million, an 81% increase from the previous year. This growth has led the company to increase its full-year revenue guidance to $130 million or more. The gross margin improved to 13%, despite a $6.7 million one-time charge due to debt refinancing. ADMA expects continued operational efficiency and profitability, aiming for $250 million in revenue by 2024 and potential margins of 40-50%. The company ended Q1 with $70 million in cash and plans to draw an additional $25 million in non-dilutive funds.

ADMA Biologics, Inc. (Nasdaq: ADMA) will announce its Q1 2022 financial results on May 11, 2022, after market close. A live conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results and other company updates. ADMA specializes in plasma-derived biologics aimed at immunodeficient patients and currently markets three FDA-approved products: ASCENIV™, BIVIGAM®, and NABI-HB®. The company operates from its Boca Raton, Florida facility and maintains FDA approval for its processes and products.

ADMA Biologics, Inc. (Nasdaq: ADMA) announced a poster presentation and Key Opinion Leader symposium on respiratory viral infections (RVIs) and ASCENIV, its FDA-approved IVIG product. The poster, presented by Dr. Kevin Rosenbach, highlights ASCENIV’s real-world outcomes for patients with primary immunodeficiency (PI) suffering from chronic respiratory infections. Additionally, discussions led by Dr. Jolan Walter and Dr. Dareen Siri will focus on the management of RVIs and clinical use of ASCENIV. ASCENIV is designed for treating primary humoral immunodeficiency, leveraging a unique plasma donor screening methodology.

ADMA Biologics has announced FDA approval to extend the shelf life of its ASCENIV and BIVIGAM immune globulin products from 24 to 36 months. This approval applies to all sizes and production scales, enhancing inventory management for healthcare providers. CEO Adam Grossman stated this milestone reflects improvements in ADMA’s manufacturing processes and supports a stronger market position amid fluctuating demand. The updated products are now available to U.S. healthcare providers, potentially increasing market penetration and addressing patient needs more effectively.

ADMA Biologics reported total revenues of approximately $81 million for full year 2021, a 92% increase from 2020. The company's gross profitability was attributed to a higher-margin product mix and increased market penetration. ADMA completed a $175 million debt refinancing with Hayfin Capital Management, extending its interest-only period to March 2027, significantly improving its cash position. For 2022, ADMA expects revenues to exceed $125 million, signifying a projected growth rate of over 50% compared to 2021.

ADMA Biologics has announced it will report its financial results for Q4 2021 and the full year on March 24, 2022, after U.S. markets close. The company, which specializes in plasma-derived biologics for immunodeficient patients, will host a conference call on the same day at 4:30 p.m. ET to discuss these results. ADMA currently markets three FDA-approved products: ASCENIV™, BIVIGAM®, and NABI-HB®. It operates an FDA-licensed facility in Boca Raton, FL, and is dedicated to treating and preventing infectious diseases.